Home Search
hepion - search results
If you're not happy with the results, please do another search
Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...
Completion of Enrollment Remains on Track for Q1, 2024
"While we recently had fireworks, we could be looking at...
Hepion Pharma (HEPA). Artificial Intelligence (AI) to Speed Drug Development.
Hepion Pharmaceuticals (HEPA) to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.
Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today.
We're beginning to believe (and...
News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10.
Of course, approval news is the ultimate "as huge as it gets" news.
But at this stage...
Remember President Trump Taking Dexamethasone? Hepion’s (HEPA) CRV431 demonstrated reduced lung inflammation and damage...
Hepion (HEPA) Announces FDA Clearance of IND Application for CRV431 for COVID-19
Hepion Pharma Doses First Patient in the ‘AMBITION’ Clinical Trial.
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH.
Adding Hepion Pharma (HEPA) $1.73 to Watch List.
Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here?
Oh my…and Oh boy....
Hepion Pharma (HEPA): News Archive
UPDATED CONTINUOUSLY..
12/31/2020: News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10.
12/23/2020: Remember...
ThinkEquity Investor Conference (NYC), Wednesday October 26th.
ThinkEquity is a boutique investment bank run by experienced professionals that have worked together for over a...
Latest article
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...
